Canadian Cancer Trials Group Bulletins

Trial Management Group


Closed to accrual IND.221

IND.221 ("A Dose-Ranging Study of IPH2201 in Patients with Gynecologic Malignancies") was closed to further accrual on April 20, 2017. Accrual to Part 1 (18 patients) and Part 2, Stage 1 (41 patients) was completed.

All patients are now off protocol treatment. Follow up of patients will continue according to the protocol.

A Dose-Ranging Study of IPH2201 in Patients with Gynecologic Malignancies
Complexity Level: 1

Primary Objectives:
To confirm the recommended phase II dose (RP2D) of single agent IPH2201 in patients with advanced/metastatic/recurrent platinum sensitive or resistant high-grade serous carcinoma (HGSC) of ovarian, fallopian tube or peritoneal origin.

Secondary Objectives:
  1. To characterize the pharmacokinetics of IPH2201 when administered as a single agent;
  2. To assess the pharmacodynamic effects of single agent IPH2201;
  3. To assess the safety and toxicity profile of single agent IPH2201;
  4. To explore the efficacy of IPH2201 in platinum resistant or sensitive HGSC;
  5. To characterize the immunogenicity of IPH2201 when administered as a single agent.
For more information please contact the study coordinator: Heather Ritter hritter@ctg.queensu.ca